<DOC>
	<DOCNO>NCT01509677</DOCNO>
	<brief_summary>The objective Biopsy trial investigate effect roflumilast 500 µg tablet daily versus placebo inflammation parameter bronchial biopsy tissue specimen additional sputum blood serum . Also data safety status obtain . Patients include required moderate severe COPD associate chronic bronchitis . The total duration randomize , multicentre , phase III trial 24 week maximum .</brief_summary>
	<brief_title>Trial Assess Anti-inflammatory Effects Roflumilast Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Major Giving write informed consent History COPD ( accord GOLD 2009 ) least 12 month prior baseline visit V0 associate chronic productive cough least three month two year prior baseline visit V0 ( cause productive cough exclude ) Outpatients 4080 year age Postbronchodilator 30 % ≤FEV1 ≤80 % predict Postbronchodilator FEV1/FVC ratio ≤70 % Current former smoker smoke history ≥20 pack year Main • Criteria affect readout parameter trial : Clinical instability , define experience COPD exacerbation six month prior V0 An upper/lower respiratory tract infection resolve four week prior V0 Diagnosis asthma and/or relevant lung disease Known alpha1antitrypsin deficiency Suspicion diagnosis bleed disorder irrespective pathophysiological mechanism Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Roflumilast</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>